News > Sanofi-GSK reports success in virus vaccine, after setback

Sanofi-GSK reports success in virus vaccine, after setback

The Sanofi-GSK vaccine was an important part of the European Union’s vaccination strategy. AP share Sanofi and GlaxoSmithKline's potential COVID-19 vaccine triggered strong immune responses in all adult age groups in preliminary trials, boosting optimism the shot may join the fight against the pandemic this year.

The drugmakers said they plan to begin late-stage trials and production in the coming weeks and hope to win regulatory approval for the vaccine before the end of 2021.